Sanofi inks $360M in cancer pact
Sanofi-Aventis has agreed to pay up to $360 million in up front and milestone payments for most of the global rights to Taiho's S-1 cancer therapy. S-1 is already approved for marketing in Japan for a variety of conditions that includes colorectal, head and neck cancer and is in Phase III for Europe and the United States. Sanofi will also pay royalties on any future sales.
- here's the report on the deal from Trading Markets
PLUS: Sanofi-Aventis' vaccine unit has been warned about problems at a Pennsylvania plant. Report
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
